Pasar al contenido principal

VIAS MOLECULARES QUE CONECTAN LA INFLAMACION CON LA RESISTENCIA A LA INSULINA Y LA HIPERTROFIA CARDIACA. ESTUDIO DE LOS EFECTOS DE LOS LIGANDOS DE PPARB/D, EL ACIDO OLEICO Y LAS ESTATINAS.

SAF2009-06939

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Nacional de Proyectos de Investigación Fundamental
Subprograma Subprograma de Proyectos de Investigación Fundamental no Orientada
Convocatoria Proyectos I+D
Año convocatoria 2009
Plan Estatal 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Unidad de gestión Subdirección General de Proyectos de Investigación
Centro beneficiario UNIVERSIDAD DE BARCELONA
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MiR-146a targets Fos expression in human cardiac cells

  • Palomer, Xavier
  • Capdevila Busquets, Eva
  • Botteri, G.
  • Davidson, Mercy M.
  • Rodríguez, Cristina|||0000-0002-6472-5647
  • Martínez-González, José|||0000-0002-3894-7166
  • Vidal, Francisco|||0000-0001-8089-4945
  • Barroso, Emma
  • Chan, Tung O.
  • Feldman, Arthur M.
  • Vázquez-Carrera, Manuel
miR-146a is a microRNA whose transcript levels are induced in the heart upon activation of NF-κB, a transcription factor induced by proinflammatory molecules (such as TNF-α) that is strongly related to the pathogenesis of cardiac disorders. The main goal of this study consisted of studying new roles of miR-146a in cardiac pathological processes caused by the pro-inflammatory cytokine TNF-α.Our results demonstrate that miR-146a transcript levels were sharply increased in cardiac ventricular tissue of transgenic mice with specific overexpression of TNF-α in the heart, and also in a cardiomyocyte cell line of human origin (AC16) exposed to TNF-α. Among all the in silico predicted miR-146a target genes, Fos mRNA and protein levels notably decreased after TNF-α treatment or miR-146a overexpression. These changes correlated with a diminution in the DNA-binding activity of AP-1, the Fos-containing transcription factor complex. Interestingly, AP-1 inhibitionwas accompanied by a reduction in matrix metalloproteinase (MMP)-9 mRNA levels in human cardiac cells. The specific regulation of this MMP by miR-146a was further confirmed at the secretion and enzymatic activity levels, aswell as after anti-miR-mediated miR-146a inhibition. The results reported here demonstrate that Fos is a direct target of miR-146a activity and that downregulation of the Fos-AP-1 pathway bymiR-146a has the capacity to inhibit MMP-9 activity. Given that MMP-9 is an AP-1 target gene involvedin cardiac remodeling,myocardial dysfunction and progression of heart failure, these findings suggest that miR-146a might be a new and promising therapeutic tool for treating cardiac disorders associated with enhanced inflammation in the heart.